Last edition
News about
Epilepsy Foundation of America and youth-led nonprofit SeizeSense launch a national PSA campaign in US cinemas to educate audiences on seizure recognition and first aid.
National Institute for Health and Care Research announces first Tessa Jowell AHP Research Fellows to advance neuro-oncology research, addressing rehabilitation and supportive care gaps for brain tumour patients across the United Kingdom.
Aisa Pharma presented Phase II RECONNOITER trial results showing AISA-021 improved attack-free days and reduced duration of Raynaud’s attacks in systemic sclerosis patients at the World Systemic Sclerosis Congress.
GSK Licenses Liver Disease Drug Linerixibat To Alfasigma In USD 690 Million Deal
GSK plc has entered into a global licensing agreement with Alfasigma S.p.A., granting the Italian drugmaker exclusive worldwide rights to develop, manufacture and commercialise linerixibat, an investigational therapy for cholestatic pruritus associated with primary biliary cholangitis (PBC).
Allarity Raises USD 20 Million From Streeterville Capital To Support Cancer Drug Pipeline
The financing was structured through a note purchase agreement under which the company issued two promissory notes: one with a principal amount of USD 10.93 million and another secured note worth USD 10 million. Together, the notes provide around USD 20 million in net proceeds to the company.
VolitionRx Completes Automation Validation For Nu.Q Vet Cancer Test In Japan
VolitionRx Limited has completed validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test in collaboration with Fujifilm Vet Systems Co. Ltd in Japan, enabling the test to be run through fully automated systems in central laboratories instead of manual plates.
Ipsen Discontinues Tazverik for Certain Cancer Uses
In addition to withdrawing Tazverik from the market, Ipsen has initiated steps to stop treatment with tazemetostat for all patients currently enrolled in the ongoing SYMPHONY-1 trial. All participants will receive standard of care, lenalidomide plus rituximab only.
PureHealth Research Launches Botanical GLP-1 Supplements to Support Natural Metabolic Health
PureHealth Research introduces a new range of plant-based GLP-1 supplements formulated with clinically studied botanicals to naturally support satiety signaling, metabolic wellness, and healthy blood sugar levels.
Jiahui International Cancer Centre in Shanghai treats a US patient with advanced Non?Small Cell Lung Cancer using Ivonescimab, an experimental immunotherapy currently available only in China.
U.S. Food and Drug Administration grants De Novo clearance to LifeVac, classifying it as a Class II medical device for use as a second-line treatment in choking emergencies.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy